-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
AIDS (HIV) is short for Acquired Immune Deficiency Syndrome, caused by infection with HIV virus
AIDS (HIV) is short for Acquired Immune Deficiency Syndrome, caused by infection with HIV virus
According to the United Nations Programme on HIV/AIDS, there are currently 38 million people living with HIV and AIDS worldwide, and the number is still growing rapidly
On April 11, 2022, a research team from the National Institutes of Health (NIH) published a paper entitled: Safety and tolerability of AAV8 delivery of a broadly neutralizing antibody in adults living with HIV: a phase in Nature Medicine, a top international medical journal.
Induction of broadly neutralizing antibodies (bnAbs) is a powerful tool for the prevention and treatment of AIDS
The study enrolled eight HIV-infected patients who had been on antiretroviral therapy for at least 3 months
The study enrolled eight HIV-infected patients who had been on antiretroviral therapy for at least 3 months
The primary endpoints of this Phase 1 clinical trial are to assess the safety and tolerability of AAV8-VRC07 treatment, determine in vivo pharmacokinetics and immunogenicity, and describe patient immune responses to the AAV8-VRC07 vector and its products
The results showed that intramuscular AAV8-VRC07 was safe and well tolerated
The results showed that intramuscular AAV8-VRC07 was safe and well tolerated
This study shows that AAV vectors can persistently generate biologically active and difficult to induce broadly neutralizing antibodies in vivo, adding a new powerful tool in the fight against infectious diseases such as AIDS
More importantly, this AAV delivery platform can produce antibodies for a long time with a single injection.
Paper link:
Safety and tolerability of AAV8 delivery of a broadly neutralizing antibody in adults living with HIV: a phase 1, dose-escalation trial .
Safety and tolerability of AAV8 delivery of a broadly neutralizing antibody in adults living with HIV: a phase 1, dose-escalation trial .
Nature Medicine.
2022.
Safety and tolerability of AAV8 delivery of a broadly neutralizing antibody in adults living with HIV: a phase 1, dose-escalation trial
leave a message here
